What’s Next? Five Things To Look Out For In February
Blockbuster Drug Set For US Competition, AAM/IGBA Conference Held In Florida
February brings a potentially sizeable launch in the US, multiple court cases in both the US and Europe and a gala generics and biosimilars event stretching across four days in Florida.
You may also be interested in...
With a leadership position in the US generics association and a new CEO focused on how to reallocate resources, Teva leaves the brand trade association after a review of the ‘effectiveness and value of engagements.’
Amgen has confirmed its long-awaited launch of Amjevita, the first US biosimilar rival to Humira, kicking off a year of competition that will also see a second wave of adalimumab products launch in six months’ time. The company has announced that it will offer the product at a 55% discount to the originator.
AbbVie CEO Richard Gonzalez has set out his expectations for Humira in 2023, with the US market on the cusp of biosimilar competition from multiple adalimumab rivals.